Urinary Incontinence Medication
- Author: Sandip P Vasavada, MD; Chief Editor: Edward David Kim, MD, FACS more...
Medication Summary
The goal of therapy is to improve the symptoms of frequency, nocturia, urgency, and urge incontinence. Treatment options include anticholinergics, antispasmodic agents, and tricyclic antidepressants (TCAs).
In patients with stress incontinence, alpha agonist treatment results in contraction of the internal urethral sphincter and increases the urethral resistance to urinary flow. Sympathomimetic drugs, estrogen, and tricyclic agents increase bladder outlet resistance to improve symptoms of stress urinary incontinence.
Pharmacologic therapy for stress incontinence and an overactive bladder may be most effective when combined with a pelvic exercise regimen. The 3 main categories of drugs used to treat urge incontinence include anticholinergic drugs, antispasmodics, and TCAs.
When a single drug treatment does not work, a combination therapy such as oxybutynin (Ditropan) and imipramine (Tofranil) may be used. Although their mechanism of action differs, oxybutynin and imipramine work together to improve urge incontinence.
Oxybutynin causes direct smooth muscle relaxation of the urinary bladder and has local anesthetic properties. Imipramine has a direct inhibitory and local anesthetic effect on the bladder smooth muscle, similar to oxybutynin; however, imipramine also increases the bladder outlet resistance at the level of the bladder neck. Thus, the combination of these drugs produces a synergistic effect to relax the unstable bladder and to hold in urine and prevent urge incontinence. Potential anticholinergic adverse effects may be additive because both drugs have similar adverse reactions.
Alpha-Adrenergic Agonists
Class Summary
The bladder neck contains a high concentration of receptors that are sensitive to alpha-agonists. Alpha-agonists increase bladder outlet resistance by contracting the bladder neck. These agents are beneficial in the treatment of mild to moderately severe stress incontinence in women.
Midodrine
The active metabolite of midodrine, desglymidodrine, is an alpha1-agonist that may increase bladder outlet resistance.
Pseudoephedrine hydrochloride (Sudafed, Genaphed, SudoGest)
Pseudoephedrine helps stress incontinence. The subjective improvement and cure rates are similar to that of phenylpropanolamine, which was recalled from the US market. Pseudoephedrine stimulates vasoconstriction by directly activating alpha-adrenergic receptors.
Phenylpropanolamine
Recalled from US market. Epinephrine stores are released under phenylpropanolamine stimulation and produce alpha- and beta-adrenergic stimulation. These effects may increase bladder outlet resistance.
Anticholinergic Agents
Class Summary
These agents represent first-line medicinal therapy in women with urge incontinence. These agents are useful in treating urinary incontinence associated with urinary frequency, urgency, and nocturnal enuresis.
Anticholinergic agents inhibit the binding of acetylcholine to the cholinergic receptor, thereby suppressing involuntary bladder contraction of any etiology. In addition, they increase the urine volume at which first involuntary bladder contraction occurs, decrease the amplitude of the involuntary bladder contraction, and may increase bladder capacity.
All anticholinergic drugs have a similar performance profile and toxicity. Potential adverse effects of all anticholinergic agents include blurred vision, dry mouth, heart palpitations, drowsiness, and facial flushing. When anticholinergic drugs are used in excess, the bladder may go into acute urinary retention.
All drugs with anticholinergic effects or side effects are contraindicated if patients have documented narrow-angle glaucoma. Wide-angle glaucoma is not a contraindication to their use.
Other contraindications to anticholinergic use are urinary retention, bowel obstruction, ulcerative colitis, myasthenia gravis, and severe heart diseases. Because of the potential for drowsiness—especially when combined with alcohol, sedatives, or hypnotic drugs—these agents may impair the patient's ability to perform hazardous activities, such as driving or operating heavy machinery.
Dicyclomine hydrochloride (Bentyl)
An anticholinergic agent with smooth muscle relaxant properties, dicyclomine blocks the action of acetylcholine at parasympathetic sites in secretory glands and smooth muscle.
Darifenacin (Enablex)
Darifenacin is an extended-release product eliciting competitive muscarinic receptor antagonistic activity. It reduces bladder smooth muscle contractions. Darifenacin has high affinity for M3 receptors involved in bladder and GI smooth muscle contraction, saliva production, and iris sphincter function. It is indicated for overactive bladder with symptoms of urge incontinence, urgency, and frequency. Swallow whole; do not chew, divide, or crush.
Solifenacin succinate (VESIcare)
Solifenacin elicits competitive muscarinic receptor antagonist activity, which results in anticholinergic effects and inhibition of bladder smooth muscle contraction. This agent is indicated for overactive bladder with symptoms of urgency, frequency, and urge incontinence. It must be swallowed whole; do not crush or chew.
Hyoscyamine sulfate (Levsin/SL, Levsin, Levsinex, Cystospaz-M, Levbid)
Hyoscyamine blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS, which in turn has antispasmodic effects. Hyoscyamine is absorbed well by the GI tract. Food does not affect absorption of this drug. Hyoscyamine is available in sublingual form (Levsin SL, Symax SL), conventional tablets (Levsin), and extended-release tablets (Levbid).
Propantheline (Pro-Banthine)
A prototypical anticholinergic agent, propantheline blocks action of acetylcholine at postganglionic parasympathetic receptor sites.
Tolterodine (Detrol and Detrol LA)
Competitive muscarinic receptor antagonist for overactive bladder. However, it differs from other anticholinergic types in that it has selectivity for urinary bladder over salivary glands. Exhibits a high specificity for muscarinic receptors, has minimal activity or affinity for other neurotransmitter receptors and other potential targets such as calcium channels. In clinical studies, the mean decrease in urge incontinence episodes was 50% and the mean decrease in urinary frequency was 17%. The mean decrease in urge incontinence episodes per wk was 53% for Detrol LA 4 mg qd.
Trospium (Sanctura)
Quaternary ammonium compound that elicits antispasmodic and antimuscarinic effects. Antagonizes acetylcholine effect on muscarinic receptors. Parasympathetic effect reduces smooth muscle tone in the bladder. Indicated to treat symptoms of overactive bladder (eg, urinary incontinence, urgency, frequency).
Fesoterodine (Toviaz)
Competitive muscarinic receptor antagonist. Antagonistic effect results in decreased bladder smooth muscle contractions. Indicated for symptoms of overactive bladder (eg, urinary urge incontinence, urgency, and frequency). Available as 4- or 8-mg extended-release tab.
Antispasmodic Drugs
Class Summary
These agents relax the smooth muscles of the urinary bladder. By exerting a direct spasmolytic action on the smooth muscle of the bladder, these medications have been reported to increase bladder capacity and effectively decrease or eliminate urge incontinence.
The adverse effect profile of antispasmodic drugs is similar to that of anticholinergic agents. These drugs may impair the ability to perform activities requiring mental alertness and physical coordination. Drinking alcohol and using sedatives in combination with these antispasmodic drugs is contraindicated.
In 2001, Appell et al reported the results of the Overactive Bladder: Judging Effective Control and Treatment (OBJECT) trial. This was a large double-blind, multicenter, prospective, randomized controlled study that compared the efficacy and tolerability of oxybutynin (Ditropan XL) (n = 160) with that of tolterodine (Detrol) (n = 170) in men and women with symptoms of overactive bladder. The study concluded that oxybutynin 10 mg was statistically superior to tolterodine 2 mg bid in terms of efficacy. However, both drugs had similar adverse-effect profiles.[58]
Oxybutynin chloride (Ditropan IR, Ditropan XL, Gelnique)
Both the immediate-release and the extended-release forms of oxybutynin have both an anticholinergic and a direct smooth muscle relaxant effect on the urinary bladder. In addition, oxybutynin provides a local anesthetic effect on the irritable bladder.
The human detrusor has M2 and M3 muscarinic receptors. The M3 receptor mediates contractile response of human detrusor. Oxybutynin has greater affinity for the M3 receptor. Urodynamic studies have shown oxybutynin increases bladder size, decreases frequency of symptoms, and delays initial desire to void.
Ditropan XL has an innovative drug delivery system: oral osmotic delivery system (OROS). The Ditropan XL tablet has a bilayer core that contains a drug layer and a "push layer" that contains osmotic components. The outer tablet is composed of a semipermeable membrane with a precision laser-drilled hole that allows the drug to be released at a constant rate.
When the drug is ingested, the aqueous environment in the gastrointestinal tract causes water to enter the tablet via semipermeable membrane at a constant rate. The introduction of water inside the tablet liquefies drug and causes the push layer to swell osmotically. As the push layer swells, it forces the drug suspension out the hole at a constant rate over a 24-h period.
Ditropan XL achieves steady-state levels over a 24-h period. It avoids first pass metabolism in liver and upper gastrointestinal tract to avoid cytochrome P450 enzymes. It has excellent efficacy, with minimal adverse effects.
Flavoxate (Urispas)
Flavoxate is used for symptomatic relief of dysuria, urgency, nocturia, and incontinence, as may occur in cystitis, prostatitis, urethritis, and urethrocystitis/urethrotrigonitis. It exerts a direct relaxant effect on smooth muscles via phosphodiesterase inhibition. It provides relief for a variety of smooth muscle spasms.
Tricyclic Antidepressants
Class Summary
Historically, these drugs were used to treat major depression; however, TCAs have an additional use in the treatment of bladder dysfunction. They function to increase norepinephrine and serotonin levels. In addition, they exhibit an anticholinergic and direct muscle relaxant effect on the urinary bladder.
Imipramine hydrochloride (Tofranil)
A typical TCA, imipramine facilitates urine storage by decreasing bladder contractility and increasing outlet resistance. It has an alpha-adrenergic effect on the bladder neck and an antispasmodic effect on the detrusor muscle. Imipramine also has a local anesthetic effect on bladder mucosa.
Amitriptyline hydrochloride (Elavil)
A TCA with sedative properties, amitriptyline increases the circulating levels of norepinephrine and serotonin by blocking their reuptake at nerve endings. It ineffective for use in urge incontinence but is extremely effective in decreasing symptoms of urinary frequency in women with pelvic floor muscle dysfunction. Amitriptyline restores serotonin levels and helps break the cycle of pelvic floor muscle spasms. It is well tolerated and effective in the majority of women with urinary frequency.
Estrogens
Class Summary
Conjugated estrogens increase the tone of urethral muscle by up-regulating the alpha-adrenergic receptors in the surrounding area, and they enhance alpha-adrenergic contractile response to strengthen the pelvic muscles, which is important in urethral support (ie, prevents urethral hypermobility). Mucosal turgor of periurethral tissue from proper nourishment enhances urethral mucosal coaptation.
The result is an improved mucosal seal effect, which is important in urethral function (ie, it prevents intrinsic sphincter deficiency). Estrogen supplementation appears to be the most effective in postmenopausal women with mild-to-moderate incontinence. Both types of stress incontinence improve with estrogen fortification.
Conjugated estrogen (Premarin)
Conjugated estrogen may be used as an adjunctive pharmacologic agent for postmenopausal women with stress or mixed incontinence. Oral or vaginal form of estrogen may be used. The usual oral dose is 0.3-1.25 mg taken daily in a cyclic regimen.
When oral estrogens are needed, prescribe 0.625-mg pills. To prevent overstimulation of the uterus, conjugate estrogen is taken once a day for 21 consecutive days, followed by 7 days without the drug (eg, 3 wk on and 1 wk off). This regimen is repeated as necessary and tapered or discontinued at 3- to 6-month intervals.
Conjugated estrogen vaginal cream is available in a package with a plastic applicator and a tube that contains 42.5 grams of conjugated estrogens. Each gram contains 0.625 mg of conjugated estrogens. When vaginal cream is used, 2-4 g (0.5-1 applicator) of the cream may be administered intravaginally daily in the usual cyclic regimen.
Estrogen cream is readily absorbed through the skin and mucous membranes. When this cream is used for treatment of atrophic vaginitis, it may be placed intravaginally or applied topically around the vaginal tissues.
When estrogen is used long term in women with an intact uterus, the addition of progestin therapy is recommended to prevent endometrial hyperplasia. Medroxyprogesterone 2.5-10 mg/d is needed for 10-13 days to provide maximum maturation of endometrium and to eliminate any hyperplastic changes. Medroxyprogesterone may be administered continuously or intermittently.
Treatment with estrogen derivatives results in few cures (0-14%) but may cause subjective improvement in 29-66% of women. Limited evidence suggests that oral or vaginal estrogen therapy may benefit some women with stress and mixed urinary incontinence. Other potential beneficial effects of estrogen use include decreased bone loss and resolution of hot flashes during menopause.
Routinely prescribing conjugated estrogens to premenopausal women is not recommended. Use this medication in postmenopausal women who are incontinent and who have had a hysterectomy. For postmenopausal women with an intact uterus, cautiously recommend a short-term low-dose of conjugated estrogen and monitor frequently.
Antidepressants, Serotonin/Norepinephrine Reuptake Inhibitors
Class Summary
Some agents in this class may improve stress incontinence
Duloxetine (Cymbalta)
Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake. Its antidepressive action is theorized to be due to serotonergic and noradrenergic potentiation in the CNS.
Alpha-Adrenergic Blockers
Class Summary
These agents have been used to decrease bladder overactivity. They have shown some success in patients who have decentralized or autonomous bladders as the result of myelodysplasia, spinal cord injury, or radical pelvic surgery.
Phenoxybenzamine (Dibenzyline)
This agent decreases bladder contractions through long-lasting, noncompetitive, alpha-adrenergic blockade of postganglionic synapses at smooth muscle and exocrine glands.
Prazosin (Minipress)
Prazosin decreases internal sphincter tone and can improve the flow of urine, improving emptying of bladder. Although doses greater than 20 mg/d usually do not increase efficacy, a few patients may benefit from dose as high as 40 mg/d. If an increase in dose is needed, give first dose of each increment at bedtime to reduce syncopal episodes.
Botulinum Toxins
Class Summary
Intradetrusor injections with botulinum toxin are a novel treatment modality that has been shown to decrease episodes of urinary leakage in patients who have failed pharmacological therapy.
OnabotulinumtoxinA (BOTOX)
Neurotoxin from Clostridium botulinum; prevents ACh release from presynaptic membrane. Indicated for urinary incontinence in patients with neurologic conditions (eg, spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. [Medline].
Nazir T, Khan Z, Barber HR. Urinary incontinence. Clin Obstet Gynecol. Dec 1996;39(4):906-11. [Medline].
Chutka DS, Fleming KC, Evans MP, Evans JM, Andrews KL. Urinary incontinence in the elderly population. Mayo Clin Proc. Jan 1996;71(1):93-101. [Medline].
Gibbs CF, Johnson TM 2nd, Ouslander JG. Office management of geriatric urinary incontinence. Am J Med. Mar 2007;120(3):211-20. [Medline].
[Guideline] Rogers RG. Clinical practice. Urinary stress incontinence in women. N Engl J Med. Mar 6 2008;358(10):1029-36. [Medline].
[Guideline] American College of Obstetricians and Gynecologists. Urinary incontinence in women. Obstet Gynecol. Jun 2005;105(6):1533-45. [Medline].
McFall S, Yerkes AM, Bernard M, LeRud T. Evaluation and treatment of urinary incontinence. Report of a physician survey. Arch Fam Med. Mar-Apr 1997;6(2):114-9. [Medline].
Wallner LP, Porten S, Meenan RT, O'Keefe Rosetti MC, Calhoun EA, Sarma AV, et al. Prevalence and severity of undiagnosed urinary incontinence in women. Am J Med. Nov 2009;122(11):1037-42. [Medline]. [Full Text].
Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. Dec 1997;104(12):1374-9. [Medline].
Abrams P, Cardozo L, Khoury S, et al, Eds. Incontinence. 4th ed. Paris, France: Health Publication Ltd; 2009:Chapter 5B.
Delancey JO, Ashton-Miller JA. Pathophysiology of adult urinary incontinence. Gastroenterology. Jan 2004;126(1 Suppl 1):S23-32. [Medline].
Dietz HP, Wilson PD. Anatomical assessment of the bladder outlet and proximal urethra using ultrasound and videocystourethrography. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(6):365-9. [Medline].
Chaikin DC, Groutz A, Blaivas JG. Predicting the need for anti-incontinence surgery in continent women undergoing repair of severe urogenital prolapse. J Urol. Feb 2000;163(2):531-4. [Medline].
Mills IW, Greenland JE, McMurray G, McCoy R, Ho KM, Noble JG, et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol. Feb 2000;163(2):646-51. [Medline].
Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. Mar 2006;175(3 Pt 2):S5-10. [Medline].
Kinder RB, Mundy AR. Pathophysiology of idiopathic detrusor instability and detrusor hyper-reflexia. An in vitro study of human detrusor muscle. Br J Urol. Dec 1987;60(6):509-15. [Medline].
Cukier JM, Cortina-Borja M, Brading AF. A case-control study to examine any association between idiopathic detrusor instability and gastrointestinal tract disorder, and between irritable bowel syndrome and urinary tract disorder. Br J Urol. Jun 1997;79(6):865-78. [Medline].
Tse V, Wills E, Szonyi G, Khadra MH. The application of ultrastructural studies in the diagnosis of bladder dysfunction in a clinical setting. J Urol. Feb 2000;163(2):535-9. [Medline].
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. Nov 1993;150(5 Pt 2):1668-80. [Medline].
Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. Sep 1999;83(5):1213-29. [Medline].
Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. Mar 1999;161(3):743-57. [Medline].
Patel AK, Chapple CR. Urodynamics in the management of female stress incontinence--which test and when?. Curr Opin Urol. Jul 2008;18(4):359-64. [Medline].
Petros PE, Woodman PJ. The Integral Theory of continence. Int Urogynecol J Pelvic Floor Dysfunct. Jan 2008;19(1):35-40. [Medline].
Crankson SJ, Ahmed S. Female bladder exstrophy. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(2):98-104. [Medline].
Wojcik LJ, Kaplan GW. The wet child. Urol Clin North Am. Nov 1998;25(4):735-44, xi. [Medline].
Steele AC, Kohli N, Mallipeddi P, Karram M. Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(2):106-10. [Medline].
Morgan JL, O'Connell HE, McGuire EJ. Is intrinsic sphincter deficiency a complication of simple hysterectomy?. J Urol. Sep 2000;164(3 Pt 1):767-9. [Medline].
Wilson MM. Urinary incontinence: selected current concepts. Med Clin North Am. Sep 2006;90(5):825-36. [Medline].
Cummings JM, Rodning CB. Urinary stress incontinence among obese women: review of pathophysiology therapy. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):41-4. [Medline].
Sustersic O, Kralj B. The influence of obesity, constitution and physical work on the phenomenon of urinary incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(3):140-4. [Medline].
Curtis LA, Dolan TS, Cespedes RD. Acute urinary retention and urinary incontinence. Emerg Med Clin North Am. Aug 2001;19(3):591-619. [Medline].
Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. Mar 2006;119(3 Suppl 1):29-36. [Medline].
Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. Sep 17 2008;300(11):1311-6. [Medline]. [Full Text].
Fultz NH, Herzog AR, Raghunathan TE, Wallace RB, Diokno AC. Prevalence and severity of urinary incontinence in older African American and Caucasian women. J Gerontol A Biol Sci Med Sci. Jun 1999;54(6):M299-303. [Medline].
Anger JT, Saigal CS, Litwin MS. The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol. Feb 2006;175(2):601-4. [Medline].
Freeman EW, Grisso JA, Berlin J, Sammel M, Garcia-Espana B, Hollander L. Symptom reports from a cohort of African American and white women in the late reproductive years. Menopause. Jan-Feb 2001;8(1):33-42. [Medline].
Howard D, Delancey JO, Tunn R, Ashton-Miller JA. Racial differences in the structure and function of the stress urinary continence mechanism. Obstet Gynecol. May 2000;95(5):713-7. [Medline]. [Full Text].
Sears CL, Wright J, O'Brien J, Jezior JR, Hernandez SL, Albright TS, et al. The racial distribution of female pelvic floor disorders in an equal access health care system. J Urol. Jan 2009;181(1):187-92. [Medline].
Daneshgari F, Imrey PB, Risendal B, Dwyer A, Barber MD, Byers T. Differences in urinary incontinence between Hispanic and non-Hispanic white women: a population-based study. BJU Int. Mar 2008;101(5):575-9. [Medline].
Castillo PA, Espaillat-Rijo LM, Davila GW. Outcome measures and definition of cure in female stress urinary incontinence surgery: a survey of recent publications. Int Urogynecol J Pelvic Floor Dysfunct. Mar 2010;21(3):343-8. [Medline].
Foley AL, Loharuka S, Barrett JA, et al. Association between the Geriatric Giants of urinary incontinence and falls in older people using data from the Leicestershire MRC Incontinence Study. Age Ageing. Jan 2012;41(1):35-40. [Medline].
Nygaard I, Holcomb R. Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):15-7. [Medline].
Dupont MC, Albo ME, Raz S. Diagnosis of stress urinary incontinence. An overview. Urol Clin North Am. Aug 1996;23(3):407-15. [Medline].
Fedorkow DM, Sand PK, Retzky SS, Johnson DC. The cotton swab test. Receiver-operating characteristic curves. J Reprod Med. Jan 1995;40(1):42-6. [Medline].
Miller JM, Ashton-Miller JA, Delancey JO. Quantification of cough-related urine loss using the paper towel test. Obstet Gynecol. May 1998;91(5 Pt 1):705-9. [Medline].
Swift SE, Yoon EA. Test-retest reliability of the cough stress test in the evaluation of urinary incontinence. Obstet Gynecol. Jul 1999;94(1):99-102. [Medline].
Summitt RL Jr, Stovall TG, Bent AE, Ostergard DR. Urinary incontinence: correlation of history and brief office evaluation with multichannel urodynamic testing. Am J Obstet Gynecol. Jun 1992;166(6 Pt 1):1835-40; discussion 1840-4. [Medline].
Jensen JK, Nielsen FR Jr, Ostergard DR. The role of patient history in the diagnosis of urinary incontinence. Obstet Gynecol. May 1994;83(5 Pt 2):904-10. [Medline].
Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. Jul 18 2007;CD005493. [Medline].
Petros PE. New ambulatory surgical methods using an anatomical classification of urinary dysfunction improve stress, urge and abnormal emptying. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(5):270-7. [Medline].
Moore KN, Schieman S, Ackerman T, Dzus HY, Metcalfe JB, Voaklander DC. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology. Jan 2004;63(1):150-4. [Medline].
Lee DI, Wedmid A, Mendoza P, et al. Bladder Neck Plication Stitch: A Novel Technique During Robot-Assisted Radical Prostatectomy to Improve Recovery of Urinary Continence. J Endourol. Sep 23 2011;[Medline].
Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. Sep 1998;105(3):236-41. [Medline].
Schuessler B. What do we know about duloxetine's mode of action? Evidence from animals to humans. BJOG. May 2006;113 Suppl 1:5-9. [Medline].
Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol. Sep 2004;104(3):511-9. [Medline].
Duckett JR, Aggarwal I, Patil A. Duloxetine treatment for women awaiting continence surgery. Int Urogynecol J Pelvic Floor Dysfunct. Nov 2006;17(6):563-5.
Cardozo L, Lange R, Voss S, Beardsworth A, Manning M, Viktrup L, et al. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Curr Med Res Opin. Feb 2010;26(2):253-61. [Medline].
Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. Apr 2001;76(4):358-63. [Medline].
Steers W, Corcos J, Foote J. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. Mar 2005;95(4):580-6.
Serra DB, Affrime MB, Bedigian MP. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. Sep 2005;45(9):1038-47.
Fehrmann-Zumpe P, Karbe K, Blessman G. Using flavoxate as primary medication for patients suffering from urge symptomatology. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(2):91-5. [Medline].
Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol. Jan 2001;97(1):116-20. [Medline].
Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. Feb 23 2005;293(8):935-48. [Medline].
[Best Evidence] Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. Oct 7 2009;CD001405. [Medline].
Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. Jun 2011;185(6):2229-35. [Medline].
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial. Eur Urol. Jul 13 2011;[Medline].
Ginsberg D, et al. Phase 3 Efficacy and Safety Study of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity. Presented at 107th Annual Meeting of the American Urological Association, Washington, DC. May, 2011.
Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. Jul 1999;162(1):3-11. [Medline].
Robson WL. Clinical practice. Evaluation and management of enuresis. N Engl J Med. Apr 2 2009;360(14):1429-36. [Medline].
American College of Obstetricians & Gynecologists. Urinary incontinence in women. National Guideline Clearinghouse. Available at http://guideline.gov/summary/summary.aspx?doc_id=10931.
Goode PS, Burgio KL, Johnson TM 2nd, Clay OJ, Roth DL, Markland AD, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. Jan 12 2011;305(2):151-9. [Medline].
Doganay M, Kilic S, Yilmaz N. Long-term effects of extracorporeal magnetic innervations in the treatment of women with urinary incontinence: results of 3-year follow-up. Arch Gynecol Obstet. Jul 2010;282(1):49-53. [Medline].
Burgio KL, Richter HE, Clements RH, Redden DT, Goode PS. Changes in urinary and fecal incontinence symptoms with weight loss surgery in morbidly obese women. Obstet Gynecol. Nov 2007;110(5):1034-40. [Medline].
[Best Evidence] Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. Jan 29 2009;360(5):481-90. [Medline]. [Full Text].
Phelan S, Kanaya AM, Subak LL, et al. Weight Loss Prevents Urinary Incontinence in Women With Type 2 Diabetes: Results From the Look AHEAD Trial. J Urol. Jan 18 2012;[Medline].
Rehder P, Haab F, Cornu JN, Gozzi C, Bauer RM. Treatment of Postprostatectomy Male Urinary Incontinence With the Transobturator Retroluminal Repositioning Sling Suspension: 3-Year Follow-up. Eur Urol. Feb 25 2012;[Medline].
Morgan JL, O'Connell HE, McGuire EJ. Is intrinsic sphincter deficiency a complication of simple hysterectomy?. J Urol. Sep 2000;164(3 Pt 1):767-9. [Medline].
Print
